For 2018, we do see a number of opportunities, including our projected above-industry growth in individual Medicare Advantage and strong growth in group Medicare Advantage products, the full year impact of 2017 capital deployment action, and the potential to deploy additional capital to improve adjusted EPS growth, the reduction of losses from exiting individual Commercial products in 2018 and our ability to achieve expense efficiencies as we continue to simplify our processes and drive for best-in-class business performance